

## CURRICULUM VITAE

1. Date revised: August 2008

### I. PERSONAL:

2. Name: **Leopoldo Raij, M. D.**  
3. Home Phone: 305-446-8351 / Fax: 305-446-8352  
4. Office Phone: 305-575-3103/ Fax: 305-575-3378  
Home Address: 3806 Solana Road, Miami, FL 33133  
Current Academic Rank: Professor of Medicine, Tenured  
University of Miami Miller School of Medicine, Miami, FL  
7. Primary Department: Department of Medicine  
8. Secondary or Joint Departmental Appointments:  
9. Citizenship: USA  
10. Visa - NA

### II. HIGHER EDUCATION

11. Institutional

#### Undergraduate:

1956 Colegio Nacional de Bahía Blanca, Argentina - B. S.

#### Medical School:

1967 Universidad Nacional del Litoral (UNL)  
MD (Included Internship and Residency)

#### Internship:

1965 Straight Medical Internship. Department of Medicine,  
University Hospital, UNL, Argentina

#### Residency-Fellowship:

1966-1968 Department of Medicine, University Hospital, U. N.L. Argentina  
1968-1970 Department of Medicine and Renal Division  
Michael Reese Hospital, Chicago, Illinois  
Chief, Victor Pollak, MD  
1970-1982 Research Associate, Pediatric Nephrology,  
University of Minnesota Medical School, Minneapolis, MN  
Director, Alfred Michael MD

12. Non-Institutional Certification:

American Board of Internal Medicine 1981  
ASH Specialist in Clinical Hypertension, October 1999

### III. EXPERIENCE

14. Academic Appointments:

- 1970-1971 Instructor, Department of Medicine, University of Minnesota Medical School (UMMS), Minneapolis, MN
- 1971-1976 Assistant Professor of Medicine, UMMS, Minneapolis, MN
- 1976-1985 Associate Professor of Medicine, UMMS, Minneapolis, MN
- 1985-2001 Professor of Medicine, UMMS, Minneapolis, MN
- 9/2001-pres. Professor of Medicine, University of Miami School of Medicine (UMSM), Miami, FL
- 9/2001- pres Director of Hypertension Renal Division, UMSM, Miami, FL
- 9/2001-pres. Vice-Chairman Vascular Biology Institute, UMSM, Miami, FL
- 4/2008-pres Director of Hypertension Hypertension and Nephrology Research, University of Miami International Medicine Institute

15. Non-Academic

- 1970-1977 Attending Physician, Department of Medicine, Hennepin County Medical Center, Minneapolis, MN
- 1977-1982 Attending Physician, Department of Medicine, University of Minnesota Hospital, Minneapolis, MN
- 1982-8/2001 Chief, Nephrology/Hypertension Section Veterans Administration Medical Center, Minneapolis, MN
- 9/2001-pres. Chief, Nephrology and Hypertension Section Veterans Affairs Medical Center, Miami, FL
- 9/2001-pres Attending Physician and Director of Hypertension, Jackson Memorial Hospital, University of Miami Miller School of Medicine

16. Military: NA

### IV. PUBLICATIONS

#### Books and monographs published:

1. Adam A, Ishani A, Koushik R and **L Raij**: Interaction of AT<sub>1</sub> receptor antagonists and their vasoactive factors. In: Angiotensin II Receptor Antagonists, M. Epstein and H.R. Brunner (eds.), Hanley & Belfus, Inc., Philadelphia, PA, Chapter 11, 2001; pp. 149-170.
2. Jaimes E, Hayakawa H and **L Raij**: The patho- and physiological effects of NO on the renal circulation. In: The Hemodynamic Effects of Nitric Oxide. RT Mathie, TM Griffith (ed.), Imperial College Press, London, 1999; pp. 343-364.
3. Westberg G, Shultz PJ and **L Raij**: Glycerol trinitrate prevents thrombosis in endotoxaemia: new use for old dynamite. In: The Biology of Nitric Oxide. Moncada S, Feelisch M, Busse R, Higgs EA (eds.), Vol. 3 (Physiological and Clinical Aspects), 1995; pp. 231-237.
4. Agarwal A and **L Raij**: Endothelial dysfunction in acute renal failure. In: Critical Care Nephrology, Ronco C, Bellomo R (eds), Kluwer Academic Publishers, Netherlands, 1997; pp. 509-532.
5. Savill J, **Raij L** and AJ Rees: Mechanisms of Vascular Injury. In: Diseases of the Kidney, 5<sup>th</sup> Edition, Schrier W, Gottschalk CW (eds.), Little, Brown and Co., Vol II, Chap XI, 1993; pp. 1993-2018.
6. Sweeney CJ and **L Raij**: Interactions of the endothelium and mesangium in glomerular injury: Potential role of calcium antagonists. In: Calcium Antagonists in Clinical Medicine. Epstein M (ed.), Hanley and Belfus, Inc., Philadelphia 1992.

7. Tolins, JP and **L Raij**: The kidney as a target organ in hypertension. In: Renovascular and Renal Parenchymatous Hypertension: Pathophysiology, Diagnosis and Management. Luscher TF, Basel, Kaplan NM (eds.), Springer Publishers, Berlin-Heidelberg-New York, 1992; pp. 353-364.
8. Sweeney C, Tolins J and **L Raij**: Hypertension in diabetes: Principles and therapeutics. In: Surgical Management of the Diabetic Patient. Bergman M, Sicard G (eds.), New York, Raven Press, 1991; pp. 125-135.
9. Rao GHR, **Raij L**, Lester B and JG White: Inhibition of agonist-induced human platelet activation by nitric oxide. Proc. Roy. Soc. Symp., Moncada S, Higgs EA (eds), Elsevier Science Publishers B. V. (Biomedical Division), New York, Chap. 37, 1990; pp. 355-367.
10. Tolins JP and **L Raij**: Modulation of systemic blood pressure and renal hemodynamic responses by endothelium-derived relaxing factor (nitric oxide), In: Nitric Oxide from L-arginine: A bioregulatory system. Moncada S (ed.), Elsevier Science Publishers B. V, 1990; pp. 463-473.
11. Romero JC and **L Raij**: The Role of the Kidney in Hypertension. Chapter, Rodicio JJ, Madrid, Spain, Salvat, Editor, 1987.
12. **Raij L** and JC Romero: The Effects of Hypertension on the Kidney. Chapter, Ed., Rodicio JJ, Madrid, Spain, Salvat, Editor, 1987.
13. **Raij L** and JP Tolins: Diabetes and hypertension: Considerations for therapy. In: Management of Hypertension: A Multifactor Approach. Hollenberg NK (ed.), 1987; pp. 121-134.
14. Keane WF and **L Raij**: Host Defenses and Infections Complications in Maintenance Hemodialysis Patients. In: Replacement of Renal Function by Dialysis, Drukker W, Parson F, Maher J, Martinus Nijoff (eds.), The Hague, The Netherlands, 1983.
15. **Raij L** and WF Keane: The Influence of Hemodynamic Factors upon Mesangial Kinetics of Macromolecules. In: Immunological Mechanisms in Renal Disease. Cummings A, Michael AF, Wilson CB (eds.), Plenum Medical Books, 1983.

#### Journal Articles:

1. Zhou MS, Schulman I, Jaimes EA, **Raij L**, Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF- $\beta$ , and fibronectin with concomitant increase in nitric oxide bioavailability. *Am J Physiol Renal Physiol*. 2008 Jul; 295(1):F53-9. Epub 2008 May 7
2. Zhou MS, Schulman IH, Jaimes EA, **Raij L**. Thiazide diuretics, endothelial function, and vascular oxidative stress. *J Hypertens*. 2008 Mar;26(3):494-500
3. Chirinos JA, Franklin SS, Townsend RR, **Raij L**, Body Mass Index and Hypertension Hemodynamic Subtypes in the Adult United States, Submitted 2008
4. Jaimes EA, Zhou MS, Pearse DD, Puzis L, **Raij L** Upregulation of cortical COX-2 in salt-sensitive hypertension: role of angiotensin II and reactive oxygen species. *Am J Physiol Renal Physiol*. 2008 Feb; 294(2):F385-92. Epub 2007 Dec 19.
5. Schulman IH, Zhou MS, Jaimes EA, **Raij L**. Dissociation between metabolic and vascular insulin resistance in aging. *Am J Physiol Heart Circ Physiol*. 2007 Jul; 293(1):H853-9. Epub 2007 Apr 1
6. Medina-Lezama, J, Zea-Diaz, MD, **Raij, L** Prevalence and patterns of hypertension in Peruvian Andean Hispanics: The PREVENCIÓN study. *Journal of the American Society*

- of Hypertension ,2007
7. **Raij, L**, Schulman I, Zhou, M Cross talk between AT1 and AT2 Potential Role in Vascular Remodeling in Humans *Hypertension* February 2007 270(2) 49 (editorial)
  8. **Raij, L** Nitric Oxide in the Pathogenesis of Cardiac Disease, *The Journal of Clinical Hypertension* December 2006 4(8) 30-39
  9. Zhou, M, Jaimes, EA, **Raij, L**: Benazepril combined with either amlodipine or hydrochlorothiazide is more effective than monotherapy for blood pressure control and prevention of end-organ injury in hypertensive Dahl rats; *J Cardiovascular Pharmacology* July 2006 48(1):857-61
  10. Schulman, IH, Aranda, P, **Raij, L**: Surgical Menopause Increases Salt sensitivity of Blood Pressure; *Hypertension* 2006 Jun; 47(6):1168-74. Epub 2006 Apr 17.
  11. Schulman, IH, **Raij, L**: Salt sensitivity and Hypertension after Menopause: Role of Nitric Oxide and Angiotensin II; *Am J Nephrol* March 2006
  12. Zhou MS, Schulman IH, Pagano PJ, Jaimes EA, **Raij L**.: Reduced NAD (P)H Oxidase in Low Renin Hypertension Link Among Angiotensin II, Atherogenesis, and Blood Pressure; *Hypertension* 2006 Jan;47(1):81-6. Epub 2005 Dec 12.
  13. Jaimes EA, Tian RX, Pearse D, **Raij L**: Up-regulation of glomerular COX-2 by angiotensin II: Role of reactive oxygen species: *Kidney Int.* 2005 Nov; 68 (5): 2143-53
  14. Leon CA, **Raij L**.: Interaction of haemodynamic and metabolic pathways in the genesis of diabetic nephropathy. *J Hypertens.* 2005 Nov; 23(11): 1931-7
  15. Ming-Sheng Zhou, Edgar A. Jaimes and **Leopoldo Raij**: Vascular but not cardiac remodeling is associated with superoxide production in angiotensin II hypertension. *J Hypertens.* 2005 Sep; 23 (9): 1737-43
  16. **Raij L**.: The pathophysiologic basis for blocking the renin-angiotensin system in hypertensive patients with renal disease. *Am J Hypertens.* 2005 Apr; 18: 95S-99S
  17. Fornoni A, **Raij L**: Metabolic syndrome and endothelial dysfunction. *Curr Hyperrens Rep.* 2005 Apr;7(2):88-95
  18. Schulman IH, Zhou MS, **Raij L**: Nitric oxide, angiotensin II, and reactive oxygen species in hypertension and atherogenesis. *Curr Hypertens Rep.* 2005 Feb; 7(1):61-7.
  19. Zhou, MS, Jaimes EA, **Raij L**: Atorvastatin prevents end-organ injury in salt-sensitive hypertension: role of eNOS and oxidant stress. *Hypertension.* 2004 Aug; 44(2):186-90.
  20. Grossman EB, Swan SK, Murihead GJ, Gaffney M, Chung M, DeRiesthal H, Chow D, **Raij, L**: The pharmacokinetics and hemodynamics of sildenafil citrate in male hemodialysis patients. *Kidney Int.* 2004 July; 66(10):367-74.
  21. Zhou's, MS, Schulman, IH, **Raij, L**: Nitric oxide, angiotensin II and hypertension. *Seminars in Nephrology* 2004: Jul; 24(4):366-78.
  22. Jaimes EA, DeMaster EG, Tian RX, **Raij L**: Stable compounds of cigarette smoke induce endothelial superoxide anion production via NADPH oxidase activation. *Arterioscler Thromb Vasc Biol.* 2004 June; 24(6):1031-6.
  23. Zhou, MS, Jaimes, EA, **Raij, L**: Statins prevent end-organ injury in salt-sensitive hypertension; role of eNOS and oxidant stress. *Hypertension* 2004; 44:186-190.
  24. Zhou, MS, Jaimes, EA, **Raij, L**: Inhibition of superoxide generation and improvement of endothelial function by amlodipine in angiotensin II-infused rats. *American Journal of Hypertension.* 2004; 17(2); 2004; 17(2):167-171.
  25. Zhou, MS, Adam A, Jaimes, EA, **Raij, L**: Increased oxidative stress linked to a functional upregulation of angiotensin II in salt-sensitive hypertension. *Hypertension* 2003; 42:945-951.
  26. Harrison-Bernard LM, Schulman IH, **Raij L**: Post ovariectomy hypertension is linked to

- increased AT1 receptor and salt-sensitivity. *Hypertension*, 2003; 42:1157-1163.
27. Zhou, M-S, Adam AG, Jaimes EA, **Raij L**: In salt-sensitive hypertension increased superoxide production is linked to functional upregulation of angiotensin II. *Hypertension* 2003; 42: 945-951.
  28. **Raij L**: End organ susceptibility as a determinant of renal disease in hypertension. *Kidney Int* 2003; 64:1923-1932.
  29. **Raij L**: Recommendations for the management of special populations: renal disease in diabetes. *Am J hypertens* 2003; 16: 46-49.
  30. Zhou MS, **Raij L**: Cross-talk between nitric oxide and endothelium-derived hyperpolarizing factor: synergistic interaction? *Journal of Hypertension* 2003; 21(8):1449-1551.
  31. Gnudi L, Viberti GC, Rodriguez V, Burt D, Cortes P, **Raij L**, Hartley B, Thomas S, Maestrini S, Gruden G: Mechanical forces upregulate GLUT-1 facilitative glucose transporter in mesangial cells *in vitro*: Evidence for GLUT-1 overexpression in glomerular hypertension. *Hypertens* (Published 2003).
  32. Leclercq B, Jaimes EA, **Raij L**: Nitric oxide synthase and hypertension. *Current Opinion in Nephrol and Hypertension* 11:185-189, 2002.
  33. **Raij L**, Veronesi M, Zhou M-S: The endothelium and the vascular protective effect of ACE inhibitors: what is the evidence from experimental and clinical studies? *Dialogues in Cardiovascular Med* 6:240-245, 2001.
  34. Jaimes E, Sweeney C, **Raij L**: Effects of the reactive oxygen species hydrogen peroxide and hypochlorite on endothelial NO production. *Hypertension* 38:877-883, 2001.
  35. Jaimes EA, Castillo DD, Rutherford MS, **Raij L**: Countervailing influence of tumor necrosis factor-alpha and nitric oxide in endotoxemia. *J Am Soc Nephrol* 12:1204-1210, 2001.
  36. Peng H, Carretero OA, **Raij L**, Yang F, Kapke A, Rhaleb NE: Antifibrotic effects of N-acetylseryl-aspartyl-Lysyl-proline on the heart and kidney in aldosterone-salt hypertensive rats. *Hypertension* 37:794-800, 2001.
  37. **Raij L**: Hypertension and cardiovascular risk factors: role of the angiotensin II-nitric oxide interaction. *Hypertension* 37:767-773, 2001.
  38. Harrison-Bernard LM, **Raij L**: Postmenopausal hypertension. *Curr Hypertens Rep* 2:202-207, 2000.
  39. Adam A, **Raij L**: Nitric oxide—angiotensin II axis in renal and cardiovascular injury. *J Nephrol* 13:211-220, 2000.
  40. **Raij L**: The endothelium in the progression of renal failure: Therapeutic implications. *Nefrología* XX: 51-53, 2000.
  41. Hayakawa H, **Raij L**: Relationship between hypercholesterolaemia, endothelial dysfunction and hypertension. *J Hypertens* 17:611-619, 1999.
  42. **Raij L**: Nitric oxide, salt sensitivity, and cardiorenal injury in hypertension. *Semin Nephrol* 19:296-303, 1999.
  43. Ishani A, **Raij L**: Hypertension, nitric oxide and end-organ damage. *Curr Opin Nephrol Hypertens* 8:237-241, 1999.
  44. Bataineh A, **Raij L**: Salt sensitivity and cardiovascular risk. *Cur Opin Nephrol Hypertens* 1: 199-203, 1999.
  45. **Raij L**, Hayakawa H: Blood pressure, endothelial dysfunction, and target organ injury. *Europ Heart J* 1:L44-L49, 1999.
  46. Bataineh A, Raij L: Angiotensin II, nitric oxide, and end-organ damage in hypertension. *Kidney Int Suppl* 68:S14-19, 1998.

47. Jaimes EA, Galceran JM, **Raij L**: Angiotensin II induces superoxide anion production by mesangial cells. *Kidney Int* 54:775-784, 1998.
48. Toto R, Shultz P, **Raij L**, Mitchell H, Shaw W, Ramjit D, Toh J, Shahinfar S: Efficacy and tolerability of losartan in hypertensive patients with renal impairment. Collaborative Group. *Hypertension* 31:684-691, 1998.
49. Hayakawa H, **Raij L**: Nitric oxide synthase activity and renal injury in genetic hypertension. *Hypertension* 31:266-270., 1998.
50. **Raij L**: Nitric oxide in hypertension: relationship with renal injury and left ventricular hypertrophy. *Hypertension* 31:189-193, 1998.
51. **Raij L**, Hayakawa H: Cardiorenal injury and nitric oxide synthase activity in hypertension. *J Hypertens* 16(Suppl 8):S69-S73, 1998.
52. Nagy J, Demaster EG, Wittmann I, Shultz P, **Raij L**: Induction of endothelial cell injury by cigarette smoke. *Endothelium* 5:251-263, 1997.
53. Janoff EN, Hayakawa H, Taylor DN, Fasching CE, Kenner JR, Jaimes E, **Raij L**: Nitric oxide production during *Vibrio cholerae* infection. *Am J Physiol* 273:G1160-G1167, 1997.
54. **Raij L**, Hayakawa H, Coffee K, Guerra J: Effect of doxazosin on endothelial dysfunction in hypercholesterolemic/antioxidant-deficient rats. *Am J Hypertens* 10:1257-1262, 1997.
55. Hayakawa H, Coffee K, **Raij L**: Endothelial dysfunction and cardiorenal injury in experimental salt-sensitive hypertension: effects of antihypertensive therapy. *Circulation* 96:2407-2413, 1997.
56. del Castillo D, Agarwal A, Jaimes EA, **Raij L**: Glomerular and vascular tissues do not down-regulate nitric oxide synthesis during protracted endotoxemia. *Kidney Int* 52:460-467, 1997.
57. Jaimes EA, Nath KA, **Raij L**: Hydrogen peroxide down-regulates IL-1-driven mesangial iNOS activity: implications for glomerulonephritis. *Am J Physiol* 272:F721-F728, 1997.
58. Hayakawa H, **Raij L**: The link among nitric oxide synthase activity, endothelial function, and aortic and ventricular hypertrophy in hypertension. *Hypertension* 29:235-241, 1997.
59. Jaimes E, Galceran JM, **Raij L**: End-stage renal disease: why aren't improvements in hypertension treatment reducing the risk? *Curr Opin Cardiol* 11:471-476, 1996.
60. Campese VM, Tawadrous M, Bigazzi R, Bianchi S, Mann AS, Oparil S, **Raij L**: Salt intake and plasma atrial natriuretic peptide and nitric oxide in hypertension. *Hypertension* 28:335-340, 1996.
61. **Raij L**, Jaimes E, del Castillo D, Guerra J, Westberg G: Pathophysiology of the vascular wall: the role of nitric oxide in renal disease. *Prostaglandins Leukot Essent Fatty Acids* 54:53-58, 1996.
62. Galceran JM, **Raij L**: The role of antihypertensive agents in preventing hypertensive glomerular damage. *Cardiol Rev* 4(2):85-92, 1996.
63. **Raij L**: Effects of ACE inhibitors and calcium channel blockers on the development of glomerular sclerosis in models of renal damage. *Nephrol Dial Transplant* 10 (Suppl 9):23-27, 1995.
64. **Raij L**, Baylis C: Glomerular actions of nitric oxide. *Kidney Int* 48:20-32, 1995.
65. Conger J, Robinette J, Villar A, **Raij L**, Shultz P: Increased nitric oxide synthase activity despite lack of response to endothelium-dependent vasodilators in postischemic acute renal failure in rats. *J Clin Invest* 96:631-638, 1995.
66. Tolins JP, Shultz PJ, Westberg G, **Raij L**: Renal hemodynamic effects of dietary protein in the rat: role of nitric oxide. *J Lab Clin Med* 125:228-236, 1995.
67. del Castillo D, **Raij L**: Pathophysiology of the interaction between mesangium and endothelium. *Contrib Nephrol* 111:29-37, 1995.

68. del Castillo D, **Raij L**, Shultz PJ, Tolins JP: The pressor effect of recombinant human erythropoietin is not due to decreased activity of the endogenous nitric oxide system. *Nephrol Dial Transplant* 10:505-508,1995.
69. Kubo SH, Rector TS, Bank AJ, **Raij L**, Kraemer MD, Tadros P, Beardslee M, Garr MD: Lack of contribution of nitric oxide to basal vasomotor tone in heart failure. *Am J Cardiol* 74:1133-1136, 1994.
70. Westberg G, Shultz PJ, **Raij L**: Exogenous nitric oxide prevents endotoxin-induced glomerular thrombosis in rats. *Kidney Int* 46:711-716, 1994.
71. **Raij L**: Glomerular thrombosis in pregnancy: role of the L-arginine-nitric oxide pathway. *Kidney Int* 45:775-781, 1994.
72. Agarwal A, Westberg G, **Raij L**: Pharmacologic management of shock-induced renal dysfunction. *Adv Pharmacol* 30:192-198,1994.
73. Tolins JP, Shultz PJ, **Raij L**, Brown DM, Mauer SM: Abnormal renal hemodynamic response to reduced renal perfusion pressure in diabetic rats: role of NO. *Am J Physiol* 265:F886-F895, 1993.
74. Hollenberg NK, **Raij L**: Angiotensin-converting enzyme inhibition and renal protection. An assessment of implications for therapy. *Arch Intern Med*153:2426-2435,1993.
75. **Raij L**, Nagy J, Coffee K, DeMaster EG: Hypercholesterolemia promotes endothelial dysfunction in vitamin E- and selenium-deficient rats. *Hypertension* 22:56-61, 1993.
76. Zarama M, **Raij L**: The effects of various antihypertensive agents on cardiovascular risk factors in patients with renal failure. *Am J Kidney Dis* 21:100-107, 1993.
77. **Raij L**, Shultz PJ: Endothelium-derived relaxing factor, nitric oxide: effects on and production by mesangial cells and the glomerulus. *J Am Soc Nephrol* 3:1435-1441, 1993.
78. Kubo SH, Rector TS, Bank AJ, Tschumperlin LK, **Raij L**, Brunsvold N, Kraemer MD: Effects of cardiac transplantation on endothelium-dependent dilation of the peripheral vasculature in congestive heart failure. *Am J Cardiol* 71:88-93, 1993.
79. Shultz P, **Raij L**: Tertatolol: a beta-blocker with unique effects on human glomerular cell function. *Cardiology* 83:51-56,1993.
80. **Raij L**: Nitric oxide and the kidney. *Circulation* 87:V26-V29, 1993.
81. Shultz PJ, **Raij L**: Effect of amlodipine on mesangial cell proliferation and protein synthesis. *Am J Hypertens* 5:912-914,1992.
82. Shultz PJ, **Raij L**: Endogenously synthesized nitric oxide prevents endotoxin-induced glomerular thrombosis. *J Clin Invest* 90:1718-1725, 1992.
83. Ma KW, Greene EL, **Raij L**: Cardiovascular risk factors in chronic renal failure and hemodialysis populations. *Am J Kidney Dis* 19:505-513, 1992.
84. Tolins JP, Stone BG, **Raij L**: Interactions of hypercholesterolemia and hypertension in initiation of glomerular injury. *Kidney Int* 41:1254-1261, 1992.
85. Greene EL, **Raij L**: Physiology and Pathophysiology of the intrarenal renin angiotensin system. *Choices in Cardiology* 6(Suppl 1):18-20, 1992.
86. Shultz PJ, **Raij L**: Effects of tertatolol on glomerular mesangial cells. *J Hypertens Suppl*, S358-S359, 1991.
87. Shultz PJ, Tayeh MA, Marletta MA, **Raij L**: Synthesis and action of nitric oxide in rat glomerular mesangial cells. *Am J Physiol* 261:F600-F606, 1991.
88. Tolins JP, **Raij L**: Antihypertensive therapy and the progression of chronic renal disease. Are there renoprotective drugs? *Semin Nephrol* 11:538-548, 1991.
89. **Raij L**: Mechanisms of vascular injury: the emerging role of the endothelium. *J Am Soc Nephrol* 2:S2-S8, 1991.

90. Tolins JP, **Raij L**: Chronic amphotericin B nephrotoxicity in the rat: protective effect of calcium channel blockade. *J Am Soc Nephrol* 2:98-102, 1991.
91. Tolins JP, Shultz PJ, **Raij L**: Role of endothelium-derived relaxing factor in regulation of vascular tone and remodeling. Update on humoral regulation of vascular tone. *Hypertension* 17:909-916, 1991.
92. Tolins JP, **Raij L**: Effects of amino acid infusion on renal hemodynamics. Role of endothelium-derived relaxing factor. *Hypertension* 17:1045-1051, 1991.
93. Shultz PJ, **Raij L**: The glomerular mesangium: role in initiation and progression of renal injury. *Am J Kidney Dis* 17:8-14, 1991.
94. **Raij L**: Hypertension, endothelium, and cardiovascular risk factors. *Am J Med* 90:13S-18S, 1991.
95. Sweeney C, **Raij L**: Pathophysiologic aspects of glomerular injury and implications for progression of renal failure. *Am J Cardiol* 68:1C-6C, 1991.
96. Tolins JP, **Raij L**: Angiotensin converting enzyme inhibitors and progression of chronic renal failure. *Kidney Int Suppl* 30:S118-S122, 1990.
97. Tolins JP, **Raij L**: Comparison of converting enzyme inhibitor and calcium channel blocker in hypertensive glomerular injury. *Hypertension* 16:452-461, 1990.
98. Rao GH, Krishnamurthi S, **Raij L**, White JG: Influence of nitric oxide on agonist-mediated calcium mobilization in platelets. *Biochem Med Metab Biol* 43:271-275, 1990.
99. Lahera V, Salom MG, Fiksen-Olsen MJ, **Raij L**, Romero JC: Effects of NG-monomethyl-L-arginine and L-arginine on acetylcholine renal response. *Hypertension* 15:659-663, 1990.
100. Tolins JP, Palmer RM, Moncada S, **Raij L**: Role of endothelium-derived relaxing factor in regulation of renal hemodynamic responses. *Am J Physiol* 258:H655-H662, 1990.
101. Shultz PJ, **Raij L**: Inhibition of human mesangial cell proliferation by calcium channel blockers. *Hypertension* 15:176-80, 1990.
102. Shultz PJ, Schorer AE, **Raij L**: Effects of endothelium-derived relaxing factor and nitric oxide on rat mesangial cells. *Am J Physiol* 258:F162-167, 1990.
103. Sweeney C, Shultz P, **Raij L**: Interactions of the endothelium and mesangium in glomerular injury. *J Am Soc Nephrol* 1:S13-S20, 1990.
104. Greene EL, **Raij L**: The role of cardiovascular risk factors in uremia and hemodialysis patients. *Nefrología* X:133-135, 1990.
105. Shultz P, Tolins JP, **Raij L**: Endothelial-derived vasoactive substances and the kidney. *The Kidney* 23:1-7, 1990.
106. Tolins JP, **Raij L**: Concerns about diabetic nephropathy in the treatment of diabetic hypertensive patients. *Am J Med* 87:29S-33S, 1989.
107. Archer SL, Tolins JP, **Raij L**, Weir EK: Hypoxic pulmonary vasoconstriction is enhanced by inhibition of the synthesis of an endothelium derived relaxing factor. *Biochem Biophys Res Commun* 164:1198-1205, 1989.
108. **Raij L**, Dalmaso AP, Staley NA, Fish AJ: Renal injury in DOCA-salt hypertensive C5-sufficient and C5-deficient mice. *Kidney Int* 36:582-592, 1989.
109. **Raij L**, Shultz PJ, Tolins JP: Possible mechanism for the renoprotective effect of angiotensin converting enzyme inhibitors. *J Hypertens Suppl* 7:S33-S36; discussion S36-S37, 1989.
110. DeMaster EG, **Raij L**, Archer SL, Weir EK: Hydroxylamine is a vasorelaxant and a possible intermediate in the oxidative conversion of L-arginine to nitric oxide. *Biochem Biophys Res Commun* 163:527-533, 1989.
111. Tolins JP, Vercellotti GM, Wilkowske M, Ha B, Jacob HS, **Raij L**: Role of platelet activating factor in endotoxemic acute renal failure in the male rat. *J Lab Clin Med* 113:316-324, 1989.

112. Ruilope LM, Miranda B, Morales JM, Rodicio JL, Romero JC, **Raij L**: Converting enzyme inhibition in chronic renal failure. *Am J Kidney Dis* 13:120-126, 1989.
113. Dalmaso AP, Falk RJ, **Raij L**: The pathobiology of the terminal complement complexes. *Complement Inflamm* 6:36-48, 1989.
114. Shultz PJ, **Raij L**: Effects of antihypertensive agents on endothelium-dependent and endothelium-independent relaxations. *Br J Clin Pharmacol* 28:151S-157S, 1989.
115. **Raij L**: The mesangium in progressive glomerular injury. *Perspectives in Hypertension and Renal Disease* 2(3):11-14, 1989.
116. **Raij L**, Luscher TF, Vanhoutte PM: High potassium diet augments endothelium-dependent relaxations in the Dahl rat. *Hypertension* 12:562-567, 1988.
117. Ruilope LM, Miranda B, Oliet A, Millet VG, Rodicio JL, Romero JC, **Raij L**: Control of hypertension with the angiotensin converting enzyme inhibitor captopril reduces glomerular proteinuria. *J Hypertens* 6:S467-S469, 1988.
118. Tolins JP, Shultz P, **Raij L**: Mechanisms of hypertensive glomerular injury. *Am J Cardiol* 62:54G-58G, 1988.
119. Tolins JP, **Raij L**: Adverse effect of amphotericin B administration on renal hemodynamics in the rat. Neurohumoral mechanisms and influence of calcium channel blockade. *J Pharmacol Exp Ther* 245:594-599, 1988.
120. Tolins JP, **Raij L**: Chronic amphotericin B nephrotoxicity in the rat, protective effect of prophylactic salt loading. *Am J Kidney Dis* 11:313-317, 1988.
121. Romero JC, **Raij L**, Granger JP, Ruilope LM, Rodicio JL: Multiple effects of calcium entry blockers on renal function in hypertension. *Hypertension* 10:140-151, 1987.
122. Kay NE, **Raij L**: Differential effect of hemodialysis membranes on human lymphocyte natural killer function. *Artif Organs* 11:165-167, 1987.
123. Luscher TF, Vanhoutte PM, **Raij L**: Antihypertensive treatment normalizes decreased endothelium-dependent relaxations in rats with salt-induced hypertension. *Hypertension* 9:193-197, 1987.
124. Luscher TF, **Raij L**, Vanhoutte PM: Endothelium-dependent vascular responses in normotensive and hypertensive Dahl rats. *Hypertension* 9:157-163, 1987.
125. Luscher TF, Raij L, Vanhoutte PM: Effect of hypertension and its reversal on endothelium-dependent relaxation in the aorta of the rat. *J Hypertension* 5:S153-S155, 1987.
126. **Raij L**, Kay NE: Effect of hemodialysis membranes on human lymphocyte natural killer function. *Contrib Nephrol* 59:17-25, 1987.
127. **Raij L**, Seel P, Korchik W, Ma KW: Hypertension and the progression of glomerulopathies. *Nefrología* VII(1):42-45, 1987.
128. **Raij L**: Cell mediated immunity in uremia. *Nefrología* VII(3):35-37, 1987.
129. Zimmerman BG, Arendshorst WJ, DiBona GF, Hostetter TH, Ploth DW, **Raij L**: Renal functional derangements in hypertension. *Fed Proc* 45:2661-2664, 1986.
130. Levine AS, Morley JE, **Raij L**: Opiates and the anorexia of uremia. *Physiol Behav* 37:835-838, 1986.
131. Kay NE, **Raij L**: Immune abnormalities in renal failure and hemodialysis. *Blood Purif* 4:120-129, 1986.
132. **Raij L**, Keane WF: Glomerular mesangium: its function and relationship to angiotensin II. *Am J Med* 79:24-30, 1985.
133. **Raij L**, Chiou XC, Owens R, Wrigley B: Therapeutic implications of hypertension-induced glomerular injury. Comparison of enalapril and a combination of hydralazine, reserpine, and hydrochlorothiazide in an experimental model. *Am J Med* 79:37-41, 1985.

134. O'Donnell MP, Kasiske BL, **Raij L**, Keane WF: Age is a determinant of the glomerular morphologic and functional responses to chronic nephron loss. *J Lab Clin Med* 106: 308-313, 1985.
135. O'Donnell MP, Michels L, Kasiske B, **Raij L**, Keane WF: Adriamycin-induced chronic proteinuria: a structural and functional study. *J Lab Clin Med* 106:62-67, 1985.
136. Keane WF, **Raij L**: Relationship among altered glomerular barrier permselectivity, angiotensin II, and mesangial uptake of macromolecules. *Lab Invest* 52:599-604, 1985.
137. Hammerschmidt DE, Goldberg R, **Raij L**, Kay NE: Leukocyte abnormalities in renal failure and hemodialysis. *Semin Nephrol* 5:91-103, 1985.
138. **Raij L**, Azar S, Keane WF: Role of hypertension in progressive glomerular immune injury. *Hypertension* 7:398-404, 1985.
139. **Raij L**, Azar S, Keane W: Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats. *Kidney Int* 26:137-143, 1984.
140. Keane WF, **Raij L**: Determinants of glomerular mesangial localization of immune complexes. Role of endothelial fenestrae. *Lab Invest* 45:366-371, 1981.
141. **Raij L**, Sibley RK, Keane WF: Mononuclear phagocytic system stimulation. Protective role from glomerular immune complex deposition. *J Lab Clin Med* 98:558-567, 1981.
142. **Raij L**, Michael AF: Immunofluorescence studies of thyroid gland in diabetes mellitus. *Lancet* 1:671, 1981.
143. Wiegand CF, Davin TD, **Raij L**, Kjellstrand CM: Severe hypokalemia induced by hemodialysis. *Arch Intern Med*, 141:167-170, 1981.
144. Keane WF, **Raij L**: Impaired mesangial clearance of macromolecules in rats with chronic mesangial ferritin-antiferritin immune complex deposition. *Lab Invest*, 43:500-508, 1980.
145. Lockey JE, Williams DN, **Raij L**, Sabath LD: Comparison of 4 and 10 days of doxycycline treatment for urinary tract infection. *J Urol* 124:643-645, 1980.
146. Michael AF, Keane WF, Raij L, Vernier RL, Mauer SM: The glomerular mesangium. *Kidney Int* 17:141-154, 1980.
147. **Raij L**, Keane WF, Oswald H, Michael A: Mesangial function in urethral obstruction in the rat. Blockade of the efferent limb. *J Clin Invest* 64:1204-1212, 1979.
148. Wiegand C, Davin T, **Raij L**, Kjellstrand C: Life threatening hypokalemia during hemodialysis. *Trans Am Soc Artif Intern Organs* 25:416-418, 1979.
149. **Raij L**, Keane WF, Michael AF: Unilateral Shwartzman reaction: cortical necrosis in one kidney following in vivo perfusion with endotoxin. *Kidney Int* 12:91-95, 1977.
150. Keane WF, Shapiro FL, **Raij L**: Incidence and type of infections occurring in 445 chronic hemodialysis patients. *Trans Am Soc Artif Intern Organs* 23:41-47, 1977.
151. Petersen NJ, Bond WW, Marshall JH, Favero MS, **Raij L**: An air sampling technique for hepatitis B surface antigen. *Health Lab Sci* 13:233-237, 1976.
152. **Raij L**, Keane WF, Leonard A, Shapiro FL: Irreversible acute renal failure in idiopathic nephrotic syndrome. *Am J Med* 61:207-214, 1976.
153. Keane WF, Danielson B, **Raij L**: Successful renal transplantation in progressive systemic sclerosis. *Ann Intern Med*, 85:199-202., 1976.
154. Rao KV, Berkseth RO, Crosson JT, **Raij L**, Shapiro FL: Letter: Immune-complex nephritis in mixed connective tissue disease. *Ann Intern Med* 84:174-175, 1976.
155. Crosson JT, Wathen RL, **Raij L**, Andersen RC, Anderson WR: Recurrence of idiopathic membranous nephropathy in a renal allograft. *Arch Intern Med* 135:1101-1106, 1975.
156. Toledo-Pereyra LH, **Raij L**, Simmons RL, Najarian JS: Role of exotoxin and bacteria in long-term survival of preserved small-bowel allografts. *Surgery* 76:474-481, 1974.

157. Rattazzi T, Wathen R, Comty C, **Raij L**, Leonard A, Shapiro F: The comparison of low flow (QD 200) to regular flow QD 500) dialysis. *Trans Am Soc Artif Intern Organs* 402-408, 1974.
158. Leonard A, **Raij L**, Shapiro FL: Bacterial endocarditis in regularly dialyzed patients. *Kidney Int* 4:407-422, 1973.
159. **Raij L**, Shapiro FL, Michael AF: Endotoxemia in febrile reactions during hemodialysis. *Kidney Int* 4:57-60, 1973.
160. Leonard A, Comty CM, Shapiro FL, **Raij L**: Osteomyelitis in hemodialysis patients. *Ann Intern Med* 78:651-658, 1973.
161. Leonard A, **Raij L**, Comty CM, Wathen R, Rattazzi T, Shapiro FL: Experience with endocarditis in a large kidney disease program. *Trans Am Soc Artif Intern Organs* 19:298-301, 1973.
162. Leonard A, Comty C, **Raij L**, Rattazzi T, Wathen R, Shapiro F: The natural history of regularly dialyzed diabetics. *Trans Am Soc Artif Intern Organs* 19:282-286, 1973.
163. **Raij L**, Hoyer JR, Michael AF: Steroid-resistant nephrotic syndrome: recurrence after transplantation. *Ann Intern Med* 77:581-586, 1972.
164. Hoyer JR, Vernier RL, Najarian JS, **Raij L**, Simmons RL, Michael AF: Recurrence of idiopathic nephrotic syndrome after renal transplantation. *Lancet* 2:343-348, 1972.
165. Westberg NG, Simmons RL, **Raij L**, Moberg AW, Kjellstrand CM, Najarian JS, Michael AF: Antiglobulin to cultured human lymphocytes does not bind to human allograft glomerular basement membrane. *Transplantation* 12:464-467, 1971.

#### Selected Abstracts

1. Zhou, MS, Jaimes, EA, **Raij, L**: The effect of Benazepril/Amlodipine vs. Benazepril/Hydrochlorothiazide vs. Monotherapy on blood pressure, oxidative stress, endothelial function and hypertensive renal injury. Submitted, 2004, Annual Scientific Meeting of the American Society of Nephrology (November 2004)
2. Zhou, MS, Schulman, IH, Jaimes, EA, **Raij, L**: Statins reduce hypertensive renal injury by downregulation of TGF- $\beta$ 1 and decreasing oxidative stress. Submitted, 2004 Annual Scientific Meeting of American Society of Nephrology (November 2004).
3. Zhou, MS, James, EA, **Raij, L**: Differential Role of Oxidative Stress and Calcineurin in Angiotensin II – Induced Cardiovascular Remodeling? 58<sup>th</sup> Annual Fall Conference and Scientific Sessions of the Council for HPR, Chicago, IL, October 2004.
4. **Raij, L**. Endothelial Dysfunction and Hypertension. Presented at the 11<sup>th</sup> Annual COSEHC National Scientific Sessions, New Orleans, LA, August 26-28, 2004.
5. **Raij, L**. American Guidelines for the Treatment of Hypertension. Presented at the 11<sup>th</sup> National/5<sup>th</sup> International Congress of Medicine, Santiago de Compostela, Spain, June 9-12, 2004.
6. Zhou, MS, Jaimes, EA, **Raij, L**: In salt-sensitive hypertension statins protect end-organ injury via increased NO production and decreased reactive oxygen species. 19<sup>th</sup> Annual Scientific Meeting of the American Society of Hypertension, New York, NY, May 18-23, 2004.
7. **Raij, L**. Angiotensin II and NO in Low Renin Salt Sensitive Hypertension. Presented at The 7<sup>th</sup> Forum on The Renin-Angiotensin System, Pisa, Italy, April 23-24, 2004.
8. Zhou M-S, Jaimes EA, Pagano PJ, **Raij L**: Contribution of NAD(P)H oxidase to oxidative stress and endothelial dysfunction in salt sensitive hypertension. Presented at the 57<sup>th</sup> Annual Fall Conference and Scientific Sessions, Washington D.C., September 23-26,

- 2003.
9. Schulman IH, Harrison-Bernard LM, **Raij L**: Salt sensitivity is a harbinger for postmenopausal hypertension and renal disease. *J Am Soc Nephrol* 14:2003.
  10. Jaimes, E, Run-Xia T, **Raij L**: Upregulation of glomerular COX-2 by angiotensin II: Role of reactive oxygen species. Presented at 57<sup>th</sup> Annual Fall Conference and Scientific Sessions, Washington D.C., September 23-26, 2003.
  11. Zhou M-S, Jaimes EA, **Raij L**: Statins lower blood pressure and end organ injury in salt sensitive hypertension: Role of cNOS and oxidative stress. Presented at 57<sup>th</sup> Annual Fall Conference and Scientific Sessions, Washington D.C., September 23-26, 2003.
  12. Zhou M-S, Jaimes EA, **Raij L**: Inhibition of superoxide generation and improvement of endothelial function by amlodipine in angiotensin ii induced hypertension. Accepted for presentation at the 18<sup>th</sup> Annual Scientific Meeting of American Society of Hypertension, New York, NY, May 13-17, 2003.
  13. Zhou M-S, **Raij L**: Increased oxidative stress and cardiac calcineurin in angiotensin II-induced hypertension. Presented at the 17<sup>th</sup> Annual Scientific Meeting of American Society of Hypertension, New York, NY, May 2002.
  14. **Raij L**: The renin-angiotensin-aldosterone axis in progressive renal cardiovascular diseases. *Giornate Nephrologique*. Presented at the Rome Nephrology Annual Conference Rome, Italy, February 21-23, 2002.
  15. Veronesi, M, Johnston B, Adam GA, **Raij L**: Candesartan, an angiotensin receptor-1 blocker, regresses hypertensive glomerular injury. Presented at the Eleventh European Meeting on Hypertension, Milan, Italy, June 2001.
  16. Veronesi, M, Johnston B, Adam GA, **Raij L**: Regression of glomerular injury in salt-sensitive hypertension. Presented at the American Society of Hypertension Meeting, May 2001.
  17. Adam A, **Raij L**: Prevention of mortality and morbidity in salt sensitive hypertension by Omapatrilat independent of its blood pressure lowering effect. Presented at the American Society of Hypertension Meeting, May 2001.
  18. **Raij L**, Swan S, Buechel K, Muirhead G, Gaffney M, Grossman E: Pharmacokinetic profile of Viagra7 (sildenafil citrate) in men with end-stage renal disease on chronic maintenance hemodialysis. *J Am Soc Nephrol* 11:A1269, 2000. Presented at the 33<sup>rd</sup> Annual Meeting of the American Society of Nephrology, Toronto, Canada, October 11-16, 2000.
  19. Adam AG, **Raij L**, Jaimes EA: Proliferation of mesangial cells (MC) in response to PDGF is linked to NADH/NADPH oxidase activation and H<sub>2</sub>O<sub>2</sub> generation. *J Am Soc Nephrol* 11:A2370, 2000. Presented at the 33<sup>rd</sup> Annual Meeting of the American Society of Nephrology, Toronto, Canada, October 11-16, 2000.
  20. **Raij L**, Johnston B: In females the hypertensinogenic effects of angiotensin II (All) are increased by estrogen deficiency. *J Hypertension*. Presented at the Tenth European Meeting On Hypertension, May 29 B Jun 3, 2000, Göteborg, Sweden.
  21. Bataineh A, **Raij L**: Normalization of blood pressure with a diuretic (indapamide) but not with a vasodilator (hydralazine) decreases vascular endothelin-1 and arrests cardiorenal injury in experimental salt sensitive hypertension. *J Am Soc Nephrol* 10: 1999. Presented at the 32<sup>nd</sup> Annual Meeting of the American Society of Nephrology, November 5-8, 1999, Miami Beach, Florida.
  22. **Raij L**, Johnston B, Harrison-Bernard LM: Role of upregulation of renal angiotensin II type I (AT<sub>1</sub>) receptor and salt-sensitivity in post ovariectomy (OVX) hypertension (HTN). *J Am Soc Nephrol* 10: 1999. Presented at the 32<sup>nd</sup> Annual Meeting of the American

- Society of Nephrology, November 5-8, 1999, Miami Beach, Florida.
23. Harrison-Bernard LM, **Raij L**: Post-ovariectomy (OVX) hypertension (HTN) is linked to up-regulation of renal angiotensin II type I (AT<sub>1</sub>) receptors and increased salt-sensitivity. *Hypertension* 34:No. 2, 336, August 1999.
  24. **Raij L**, Johnston B, Coffee K: Does functional upregulation of angiotensin II (Ang II) mediate end-organ injury in salt sensitive hypertension? Presented at the Ninth European Meeting of Hypertension, June 11-15, 1999 in Milan, Italy.
  25. Jaimes EA, Galceran JM, **Raij L**: Angiotensin II induces superoxide anion production by mesangial cells via AT<sub>1</sub> receptors. Presented at The 2<sup>nd</sup> International Symposium on Angiotensin II Antagonism Hampton Medical Conferences Ltd, February 15-18, 1999, London, UK.
  26. Jaimes EA, Galceran JM, **Raij L**: Losartan (LOS) blocks angiotensin II (Ang II) induction of superoxide anion (O<sub>2</sub><sup>-</sup>) production by mesangial cells (MC). Presented at the International Forum on Angiotensin II Receptor Antagonists, January 28-30, 1999, Monte-Carlo.
  27. **Raij L**: Is hypertension a nitric oxide (NO) deficient state? *Am J Hyperten*, 12(No.4), part 2, p. 217A, 1999.
  28. Jaimes EA, Galceran JM, **Raij L**: Losartan (LOS) blocks angiotensin II (Ang II) induction of superoxide anion (O<sub>2</sub><sup>-</sup>) production by mesangial cells (MC). Presented at the International Forum on Angiotensin II Receptor Antagonists, January 28-30, 1999, Monte Carlo.
  29. **Raij L**, Johnston B, Coffee K: Does functional upregulation of angiotensin II (Ang II) mediate end-organ injury in salt sensitive hypertension? Presented at the Ninth European Meeting of Hypertension, June 11-15, 1999 in Milan, Italy.
  30. Jaimes EA, Galceran JM, **Raij L**: Angiotensin II induces superoxide anion production by mesangial cells via AT<sub>1</sub> receptors. Presented at the 2<sup>nd</sup> International Symposium on Angiotensin II Antagonism Hampton Medical Conferences Ltd, February 15-18, 1999, London, U.K.
  31. Harrison-Bernard LM, **Raij L**: Post-ovariectomy (OVX) hypertension (HTN) is linked to upregulation of renal angiotensin II type I (AT<sub>1</sub>) receptors and increased salt-sensitivity. *Hypertension* 34:No. 2, 336, Aug, 1999.
  32. **Raij L**: Is hypertension a nitric oxide (NO) deficient state. *Am J Hyperten*, 12, (No.4), part 2, p. 217A, 1999.
  33. **Raij L**, Jaimes E, Hayakawa H: Development of post-ovariectomy hypertension is linked to salt sensitivity. *Hypertension*, September 1998:601, No. 68.
  34. **Raij L**, Jaimes EA, Hayakawa H: Development of post-ovariectomy hypertension is linked to salt sensitivity. *J Am Soc Nephrol* 9:315A, 1998.
  35. Jaimes EA, Rutherford MS, **Raij L**: Countervailing influence of the TNF and nitric oxide (NO) in endotoxemia. Critical role of the TNF receptors. *J Am Soc Nephrol* 9:477A, 1998.
  36. Hayakawa H, Coffee K, **Raij L**: Does vascular nitric oxide synthase activity mitigate end-organ injury in hypertension? *Am J Hyperten* 10:160A-165A, 1997.
  37. Hayakawa H, Coffee K, Guerra J, **Raij L**: Cardio-renal protection by the angiotensin II blocker irbesartan in salt sensitive hypertension. *Am J Hyperten* 10:94A-99A, 1997.
  38. Jaimes E, **Raij L**, Croat A, Nath K: Interleukin-1 (IL-1) antagonizes oxidant-induced expression of hemo oxygenase-1 (HO-1) mRNA and activity in rat mesangial cells. *J Am Soc Nephrol* 8:475A, 1997.
  39. Hayakawa H, Coffee K, Guerra J, **Raij L**: Cardio-renal protective effects of the

- angiotensin II receptor antagonist, irbesartan, in salt-sensitive hypertension. Presented at the Eighth European Meeting on Hypertension in Milan, Italy, June 13-16, 1997.
40. Guerra J, Coffee K, Hayakawa H, **Raij L**: Prevention of endothelial dysfunction by doxazosin in hypercholesterolemic antioxidant deficient rats. Presented at the 11<sup>th</sup> Scientific Meeting of American Society of Hypertension, May 15-18, 1996, New York NY.
  41. Hayakawa H, **Raij L**: Disparate effects of antihypertensive therapy on endothelial dysfunction, LVH and renal injury in salt sensitive hypertension. Presented at the 16<sup>th</sup> Scientific Meeting of the International Society of Hypertension, June 23-27, 1996 in Glasgow, United Kingdom.
  42. **Raij L**, Coffee K, Guerra J, Hayakawa H: Endothelial dysfunction in hypercholesterolemic antioxidant deficient rats is prevented by the -1 blocker doxazosin. Presented at the Second International Conference on Lipoprotein Oxidation and Atherosclerosis Biological and Clinical Aspects, Sep 12-14, 1996, in Pavia, Italy.
  43. Hayakawa H, **Raij L**: Genetically determined heterogeneity of endothelial nitric oxide (NO) synthase activity in hypertension (HTN). Presented at the 50<sup>th</sup> Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure Research, Sep 17-20, 1996, in Chicago IL.
  44. Haykawa H, Coffee K, **Raij L**: Nitric oxide synthase activity is enhanced in the vasculature and renal medulla of spontaneously hypertensive rats, but fails to control hypertension. *J Am Soc Neph* Sep 1996;7: (No.9):A1562.
  45. Jaimes E, **Raij L**: Critical role of nitric oxide (NO) in IL-1 induced PGE2 synthesis by mesangial cells (MC). *J Am Soc Neph* Sep 1996 7:(No.9):A1993.
  46. Galceran JM, James EA, **Raij L**: Pathogenetic role of angiotensin II (Ang II) in glomerular injury: Is superoxide (O<sub>2</sub><sup>-</sup>) the missing link? *J Am Soc Nephrol* Sep 1996 7:(No.9):A1914.
  47. Hayakawa H, Guerra J, Coffee K, **Raij L**: Contrasting effects of antihypertensive therapy on systemic endothelial dysfunction and glomerular injury in salt sensitive hypertension. Presented at the 29<sup>th</sup> Annual Meeting of the American Society of Nephrology, November 5-8, 1995, San Diego, CA.
  48. Jaimes E, Nath K, **Raij L**: Postranscriptional modulation of IL-1 induced nitric oxide (NO) synthesis by H<sub>2</sub>O<sub>2</sub> in rat mesangial cells (MC). Presented at the 29<sup>th</sup> Annual Meeting of the American Society of Nephrology, November 5-8, 1995, San Diego, CA.

## **V. PROFESSIONAL**

### **Editorial Board Memberships:**

Associate Editor *Journal of the American Society of Hypertension* 2006-present  
Member, Editorial Board, *Hypertension* 2001-present  
Member, Editorial Board, *Kidney International* 2000-present  
Section Editor: *Vascular Mechanisms (Current Hypertension Reports* 2004 -2005)  
*Fundamental and Clinical Pharmacology*  
*American Journal of Hypertension* (2001-2006)  
*American Journal of Hypertension (Spanish Edition* 2001-2006)  
Member Editorial Board, *Endothelium* 2002- present

### **Reviewer:**

*Kidney International*  
*American Journal of Physiology*

Journal of the American Society of Nephrology  
Journal of the American Society of Hypertension  
New England Journal of Medicine  
Diabetes  
Journal of Pharmacology and Experimental Therapeutics  
Journal of Cardiovascular Pharmacology  
Hypertension  
Journal of Clinical Investigation  
American Journal of Kidney Diseases  
Circulation  
Atherosclerosis Thrombosis and Vascular Biology

**Professional and Honorary Organizations past and present:**

Member, American Society of Nephrology  
Member, American Federation for Medical Research  
Member, American Society for Pharmacology and Experimental Therapeutics  
Member, International Society of Nephrology  
Member, Grant Review Board, Kidney Foundation of the Upper Midwest  
Member, National Kidney Foundation  
Member, American Society of Hypertension  
Member, Midwest Salt & Water Club  
Fellow, Society for Vascular Medicine and Biology  
Member, Inter-American Society of Hypertension  
Council for High Blood Pressure Research, American Heart Association  
Member, Publications Committee, Council for High Blood Pressure  
Research, American Heart Association  
AHA Scientific Sessions Program Committee  
Fellow, Council for High Blood Pressure Research, American Heart Association  
Member, International Society of Hypertension  
Member, Spanish Society of Hypertension -2007

**24. Honors and Awards (selected):**

**Doctor in Medicine, Magna Cum Laude, Universidad Nacional del Litoral, Argentina**

Co-Chairman: Organizing Committee, Symposium for Immunological, Mechanisms in Renal Disease, NIH, Bethesda, Maryland, October 1978

Session Chairman: Immunology and Pathology, Clinical, IX International, Congress of Nephrology, Los Angeles, California, 1984

Co-Chairman: Current Concepts in Anti-hypertensive Therapy, Boston University School of Medicine, August and September 1989

Co-Chairman: Hypertension Session, Central Society for Clinical Research, Chicago, IL, November 1989

Co-Chairman: Hypertension Session, American Society of Nephrology, Washington, DC, December 1989

Chairman - Satellite Symposium, American Society of Nephrology, "Nephrology Issues for

the 90's"

Member: American Society of Hypertension Scientific Program Committee 1992,  
Pfizer Labs Visiting Professorships in Cardiovascular Medicine, Sixth Annual Awards  
National Speaker for the American Society of Nephrology, National Kidney Foundation

**Lewis-Dahl American Heart Association Award, Anaheim, CA, November 2001**

Milestones in Nephrology Recurrence of Idiopathic Nephrotic Syndrome after Renal Transplantation, J Am Soc Nephrology 12:1994-2002, 2001

Chair, Annual Meeting of the COSEHC

Faculty Member, National Kidney Foundation Clinical Meetings, 2004

Chair: Hypertension in Hispanics: A Public Health Problem, The American Society of Hypertension, Inc. April 2005

**Nephrology Forum" 2002 Kidney International**

American Society of Hypertension 2002-2008

**Doctor Honoris Causa Sociedad Mejicana De Hipertensión October 2006**

**Honorary Member Award, Spanish Society of Hypertension, 2007**

Specialist in Clinical Hypertension, the American Society of Hypertension 2004-2009

Co-Chair Inter-American Society of Hypertension Miami, 2007

**Other Professional Activities:**

**A. ADVISORY COMMITTEES AND STUDY SECTIONS PAST AND PRESENT:**

Member, Advisory Board, Clinical Research Center, University of Minnesota, Medical School, Minneapolis, Minnesota

*Ad Hoc* Research Grant Reviewer for the Veterans Administration

Grant Reviewer for the National Institute of Health, Current

Grant Reviewer for the Kidney Foundation of the Upper Midwest

Grant Reviewer for the Viking Research Fund

Member, Review Board, Cardiovascular Regulation Research Study Committee, American Heart Association, July 1992 – 1996

**Member, Review Board, Cardiorenal Study Committee AHA, 7/95 - 6/97**

Chairman, Research and Development Committee, Veterans Administration, Medical Center, Minneapolis, Minnesota

Member, Merit Review Board of Department of Veterans Administration

Member of the Scientific Research Board of the American Society of Hypertension

Member of National Kidney Foundation Council on Hypertension

Member of the Scientific Advisory Board of the National Kidney Foundation

Member, emeritus capacity, Council Executive Committee, National Kidney Foundation

Member of the Executive Committee, Council on the Kidney in Cardiovascular Disease, American Heart Association, July 1994 to 1996

Chairman of the Membership Executive Committee, Council on the Kidney in Cardiovascular Disease, American Heart Association, July 1995 to 1998

Member, Nominating and Membership Committee Council for High Blood Pressure Research, American Heart Association

Member, Publications Committee, Council for High Blood Pressure Research, American Heart Association

Member, AHA Scientific Sessions Program Committee, Council for High Blood Pressure Research, American Heart Association

Member, Research Space Subcommittee, Miami, FL January 2002 to December 2002

Member, End-point Committee RENAAL Study (Completed on 2001)

Associate Editor, American Society of Hypertension (beginning 2007)

Member, Scientific Misconduct Committee, University of Miami

Member, Scientific Awards Committee (SAC), University of Miami

NIH- Member of the review board of the Center for scientific review NIH 2005-present

President of the Carolina/Florida Chapter of the American Society of Hypertension

October 2007

---

**B. SELECTED VISITING PROFESSORSHIPS AND SPECIAL LECTURES**

**1. Distinguished Lectures:**

“Mechanisms of Glomerular Injury, Royal Post-Graduate Medical School,” Hammersmith Hospital, London, England, March, 1986.

The International Symposium on ACE Inhibition, Queen Elizabeth II Conference Centre, London UK, February 14-19, 1989.

European Society of Hypertension, June, 1989, Milan, Italy.

**Special Mini-Symposium on Nitric Oxide in Relationship with the Nobel**

Prize given to nitric oxide at the American Society of Nephrology Meeting, Miami, 1999.

Guest Speaker, XIth International Congress of Nephrology, Tokyo, Japan, July 19, 1990.

Guest Speaker, 2<sup>nd</sup> International Symposium on Endothelium-Derived Vasoactive Factors, Basel, Switzerland, April 21-25, 1992.

Guest Speaker, “Novel Therapeutic Targets for Circulatory Shock”, the fourth William Harvey Research Conference, London, England, January 26-27, 1993.

Guest Speaker, Annual meeting of the Swedish Society of Nephrology, Uppsala, Sweden, May 26, 1994.

Guest Speaker, Conference on the Pathogenesis of Hypertension, Sapporo, Japan, September 9, 1995.

Invited Speaker, American Heart Association 54<sup>th</sup> Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure Research, Workshop on Growth and Death of Cardiovascular Cells: Mechanisms and implications for Cardiovascular Remodeling and Injury, Angiotensin II, Nitric Oxide and Cardioresenal Injury in Hypertension: From the Laboratory to the Bedside. Washington DC, October 24, 2000.

Invited speaker, The 7<sup>th</sup> Forum on The Renin-Angiotensin System, Rome, Italy, April 2004.

**B. SELECTED VISITING PROFESSORSHIPS AND SPECIAL LECTURES (CONTD.)**

Latin American Congress of Nephrology, Buenos Aires, Argentina, 1974.

University of Texas, Department of Medicine, San Antonio, Texas, 1975.

Guest Speaker, University of Miami, Division of Renal Medicine and Hypertension, 1977.

Co-Chairman: Organizing Committee, Symposium for Immunological Mechanisms in Renal Disease, NIH, Bethesda, Maryland, October 1978

Visiting Professor, University of Litoral, Argentina, 1979.

Visiting Professor, Universidad Federal do Rio Grande do Sul, Porto Alegre, Brazil, 1979.

Course, “Progress in Nephrology,” Argentinean Society of Internal Medicine, Buenos Aires, Argentina, 1979.

Guest Speaker, “Macromolecular Transit in the Mesangium”, Royal Post-Graduate Medical School, Hammersmith Hospital, London, England, 1979.

Guest Speaker, Veterans Administration Medical Center and Department of Medicine, School of Medicine; San Juan, Puerto Rico, 1981.

Guest Speaker, Second International Symposium. Central National Dialysis and Transplant,

Caracas, Venezuela, 1981.

Visiting Professor, Universities of Salamanca, Madrid, Barcelona, Spain, 1982.

Guest Speaker, University of Washington Medical School and Seattle Veterans Administration Medical Center, Seattle, Washington, 1982.

Guest Speaker, International Nephrology Symposium, Rosario, Argentina, 1982.

Session Chairman: Immunology and Pathology, Clinical, IX International Congress of Nephrology, Los Angeles, California, 1984

Guest Speaker, Latin American and Argentine Congress of Nephrology, Cordoba, Argentina, 1984.

Guest Speaker, "Factors Affecting Glomerular Mesangial Traffic of Macromolecules," Satellite Symposium on IXth International Congress of Nephrology - "Glomerular Function: Regulation in Normal and Pathophysiologic Conditions," Scripps Institute of Oceanography, LaJolla, California, 1984.

Guest Speaker, "Renal Function and Hemodynamics in Hypertension: Therapeutic Considerations," Satellite Symposium of the American Heart Association Meetings: Significance of the Renal Mesangial System: Its Function and Relationship to Angiotensin II. Miami, Florida, November 11, 1984.

Guest Speaker, Mexican Institute of Nephrologic Investigations, XXXIII Annual Meeting, Acapulco, Mexico, December 12-16, 1984.

Guest Speaker, University of Michigan Medical Center, Ann Arbor, Michigan, February 4, 1985.

Guest Speaker, Henry Ford Memorial Hospital, Hypertension Research Center, Detroit, Michigan, February 5, 1985.

Guest Speaker, "Models of Renal Hypertension," 15<sup>th</sup> Annual Postgraduate Nephrology Seminar. Current Methodologies in Renal Research: A Workshop sponsored by American Heart Association. May 12-15, 1985, Rochester, MN.

Guest Speaker, "Role of Hypertension in Progressive Glomerular Injury in Glomerulonephritis," Invited lecturer at The Inter-American Society of Hypertension VI Scientific Meeting, Cleveland, Ohio, May 20-21, 1985.

Guest Speaker, "Role of Salt-induced Hypertension and Dietary Protein in Progressive Glomerular Injury," American Society of Physiology, 36<sup>th</sup> Annual Fall Meeting, Niagara Falls, New York, October 13-18, 1985.

Guest Speaker and Visiting Professor of Societe Quebecoise de Nephrologie, Montreal, Quebec, Canada, April 24-27, 1986.

Guest Speaker, "Role of Hypertension in Focal Segmental Glomerulosclerosis," workshop by the Medical Committee of the Royal Netherlands Academy of Arts and Sciences, Physiology and Pathophysiology of Glomerular Filtration, Netherlands, May 21-22, 1987.

Visiting Professor, Seminar at INSERM (France equivalent of NIH). Laboratory of Dr. E. Pirotsky. Paris, France, May 25-26, 1987.

Visiting Professor, "IX Reunion de la Liga Espanola para la Lucha Contra la Hipertension Arterial." Arterial Hypertension Symposium, April 22-25, 1987, Salamanca, Spain.

Visiting Professor, University of Cordoba, November 25-29, 1987, Cordoba, Argentina.

Guest Speaker, Meeting of the Argentine Society of Hypertension, November 30-December 2, 1987, Cordoba, Argentina.

Guest Speaker, Henry Ford Hospital, February 22, 1988, Detroit, Michigan.

Guest Speaker, "Mechanisms of Glomerular Injury in Hypertension: Therapeutic Strategies." Lutheran General Hospital in Park Ridge, IL, March 31, 1988.

Guest Speaker, 10<sup>th</sup> Meeting of the Spanish League Against Hypertension, Granada, Spain, April 13-16, 1988.

Guest Speaker, Meeting of the Andalusian Nephrology Services, Malaga, Spain, April 20-25, 1988.

Visiting Professor, Grand Rounds, VAMC, Washington, D.C., June 7, 1988.

Guest Speaker, American Society of Hypertension, New York, NY, June 20-24, 1988.

Visiting Professor, FASEB Summer Research Conferences, August 7-12, 1988, Copper Mountain, Colorado.

Guest Speaker, Grand Rounds and Post Graduate Lecture, Queen's University, Department of Medicine, Division of Nephrology, Kingston, Ontario, Canada, September 14-15, 1988. "Prevention of Glomerular Damage after Prolonged Hypertension."

Co-Chairman: Current Concepts in Anti-hypertensive Therapy, Boston University School of Medicine, August and September 1989.

Co-Chairman: Hypertension Session, Central Society for Clinical Research, Chicago, IL, November 1989.

Co-Chairman: Hypertension Session, American Society of Nephrology, Washington, D.C., December 1989.

Guest Speaker, 8<sup>th</sup> Scientific Meeting Inter-American Society of Hypertension, San Juan, Puerto Rico, May 14-17, 1989.

Guest Speaker, Diabetes and Hypertension, Wayne State University School of Medicine, June 2, 1989, Detroit, MI. "Concerns About Diabetic Nephropathy in the Treatment of the Diabetic Hypertensive".

Visiting Professor, University of Pisa, Italy, June, 1989.

Guest Speaker, Renovascular Effects of Angiotensin II, Budapest, Hungary, July 16-19, 1989. "ACE Inhibitors and Progression of Renal Failure."

Visiting Professor, Rush Medical School, Chicago, IL, August, 1989.

Guest Speaker, Current Concepts in Antihypertensive Therapy, Boston University School of Medicine, Naples, Florida, August 17-20, 1989. "Pathophysiologic Aspects of Renal Injury in Hypertension."

Visiting Professor, Hospital Brussais, Paris, France, September, 1989.

Guest Speaker, Mechanisms of Glomerular Injury in Hypertension, Geneva, Switzerland, September, 1989.

Visiting Professor, University of Basel, Basel, Switzerland, September, 1989.

Guest Speaker, National Kidney Foundation, Philadelphia, PA, September, 1989.

Guest Speaker, 58<sup>th</sup> Annual Meeting of the Royal College of Physicians and Surgeons of Canada, Edmonton, Alberta, September 21, 1989. "The Endothelium in Hypertension."

Guest Speaker, Current Concepts in Antihypertensive Therapy, Coronado, California, September 21-24, 1989. "Pathophysiologic Aspects of Renal Injury in Hypertension."

Guest Speaker, National Kidney Foundation Meeting, Houston, Texas, November 1989.

Guest Speaker, Kidney in Hypertension, InterAmerican Society of Dialysis and Transplantation, Puerto Rico, November 1989.

Guest Speaker, 22<sup>nd</sup> Annual Meeting of the American Society of Nephrology, "Calcium Antagonists & Renal Function" Future Perspectives", Washington, D.C., December 1989.

Visiting Professor and Guest Speaker, Spanish Society of Nephrology, Canary Islands, Spain, January 1990.

Visiting Professor, University of Miami School of Medicine, Miami, Florida, March, 1990.

Visiting Professor and Guest Speaker, XII Annual Meeting of the Spanish League Against Arterial Hypertension, Oviedo, Spain, April, 1990.

Visiting Professor, Technion-Israel Institute of Medicine, Haifa and the Chaim Sheba Medical Center, Tel-Aviv University, Israel, April and May, 1990.

Guest Speaker, 44<sup>th</sup> Annual Fall Conference and Scientific Sessions, Council for High Blood Pressure Research, Baltimore, Maryland, September 12-15, 1990.

Guest Speaker, Seminars in Nephrology, Verona, Italy, September, 1990.

Visiting Professor, UCLA Renal Conferences, October 1990.

Guest Speaker, National Kidney Foundation Annual Meeting, Washington, December 1990.

Program Chairman, American Society of Nephrology, "Nephrology Issues for the 90's," Washington D. C., December 3-4, 1990.

Guest Speaker, International Symposium, "Multiple Risk Factors in Cardiovascular Disease," December 10-12, 1990.

Visiting Professor, Cedars-Sinai Medical Center, Los Angeles, California, December 1990.

Guest Speaker, Venezuelan Congress of Nephrology, Caracas, Venezuela, January 26-31, 1991.

Guest Speaker, Renal Physicians Association, Tempe, Arizona, February 22-24, 1991.

Guest Speaker, Sociedad Mexicana de Nefrología, A. C., Cuernavaca, Mexico, Feb. 15-16, 1991.

Visiting Professor, University of Southern California, Department of Medicine, Los Angeles,

California, March 21-22, 1991.

Visiting Professor, Round Table Discussion, Portugal University, Lisbon, Portugal, April 6, 1991.

Visiting Professor, Hospital 12 de Octubre, Madrid, Spain, April 8-10, 1991.

Guest Speaker, Satellite Symposium, "Combined Management of Cardiovascular Risk Factors," Valencia, Spain, April 11, 1991.

Visiting Professor, Indiana University, Indianapolis, Indiana, April 24, 1991.

Visiting Professor, University of Wisconsin, Madison, Wisconsin, April 29, 1991.

Guest Speaker, American Society of Hypertension, New York, May 15-18, 1991.

Guest Speaker, National Kidney Foundation, Los Angeles, California, June 1, 1991.

Guest Speaker, Fifth European Meeting on Hypertension, Milan, Italy, June 7-10, 1991.

Guest Speaker, North American Society for Dialysis and Transplantation, Maui, Hawaii, July 7-11, 1991.

Guest Speaker, Brazilian Congress of Cardiology, Sao Paulo, Brazil, Sept. 15-19, 1991.

Guest Speaker, Jornadas Madrilenas Hipertension' 91, Madrid, Spain, Sept. 26-27, 1991.

Guest Speaker, National Kidney Foundation Symposium, "The Kidney and Hypertension," Washington, D.C., October 5, 1991.

Visiting Professor, Hospital "Prnceps d' Espanya," de Bellvitge, Barcelona, Spain, October 20-23, 1991.

Guest Speaker, Simposi Internacional Sobre Inhibidors de L'Enzim de Conversio' de L'Angiotensina, Barcelona, Spain, October 24-25, 1991.

Guest Speaker, "Calcium Antagonists and the Kidney: Emerging Perspectives," American Society of Nephrology Annual Meeting, Baltimore, Maryland, November 17, 1991.

Program Chairman, "Nephrology Issues for the Nineties," American Society of Nephrology Annual Meeting, Baltimore, Maryland, November 19, 1991.

Guest Speaker, Joslin Diabetes Center, Boston, Massachusetts, Nov. 21-23, 1991.

Visiting Professor, "Berliner Gesellschaft fur Nephrologie," Berlin, Germany, Feb. 22-26, 1992.

Visiting Professor, George Washington University Medical Center, Washington, D.C., March 25-27, 1992.

Visiting Professor, "Hypertension: Diagnosis & Treatment of Secondary Hypertension," Hahnemann University, Philadelphia, PA., May 5-6, 1992.

Program Chairman, "Seventh Scientific Meeting of the American Society of Hypertension," New York, NY., May 6-9, 1992.

Guest Speaker, "Hypertension in Diabetes," Cape Coral Hospital, Cape Coral, Fl., May 21, 1992.

Guest Speaker, "VIII Congreso Argentino De Nefrologia," Buenos Aires, Argentina, June 2-6, 1992.

Guest Speaker, "The Expanding Role of Calcium Channel Blockers," Rye Town, NY, June 6, 1992.

Guest Speaker, Satellite Symposia "14<sup>th</sup> Scientific Meeting of the International Society of Hypertension," Madrid, Spain, June 14-18, 1992.

Guest Speaker, "3<sup>rd</sup> International Symposium on Recent Advances on Cardiology," Porto, Portugal, June 19-21, 1992.

Program Faculty Member and Speaker, "Evolving Concepts in the Management of Hypertension," Seville, Spain, June 21, 1992.

Program Chairman, "Renal Hemodynamics: Interactions with Endothelial and Epithelial Systems," FASEB Summer Research Conference, Saxtons River, Vermont, June 28-July 3, 1992.

Guest Speaker, Symposium, St. Luc Hospital and Notre-Dame Hospital, Montreal, Quebec, September 10-11, 1992.

Guest Speaker, Satellite Symposium, Royal College of Physicians and Surgeons of Canada, Ottawa, Ontario, September 11, 1992.

Guest Speaker, "XII Congreso Colombiano de Medicina Interna," Bogota, Colombia, August 29-September 2, 1992.

Guest Speaker, Internal Medicine Grand Rounds: "Renal Issues in Hypertension: New Data and Directions for Long-term Patient Care," University of Massachusetts Medical Center, Worcester, MA.

Guest Speaker, "4<sup>th</sup> Verona Seminar on Nephrology, Hypertension: Cause and Consequence of Renal Damage," Verona, Italy, September 17 -19, 1992.

Guest Speaker, "I Congreso HispanoAmericano De Nefrologia", Barcelona, Spain, October 4-8, 1992.

Guest, Round Table discussion - Hospital Princepo de Espana, Barcelona, Spain, October 8, 1992.

Guest Speaker, Boston Diabetes Symposium, Boston, Massachusetts, October 8-11, 1992.

Guest Speaker, Hypertension Symposium, Danbury Hospital, Danbury, Connecticut, October 21, 1992.

Visiting Professor, University of Utah, Salt Lake City, Utah, November 7, 1992.

Program Chairman, National Kidney Foundation, Baltimore, Maryland, November 12-15, 1992.

Program Chairman, "3<sup>rd</sup> Annual, Nephrology Issues for the Nineties", Satellite Symposium at the Annual Meeting of the American Society of Nephrology, Baltimore, Maryland, November 16, 1992.

Guest Speaker, American Society of Nephrology Meeting, Baltimore, Maryland, November 15-18, 1992.

Guest Speaker, Grand Rounds, Ottawa Heart Institute, Ottawa, Ontario, December 10, 1992.

Guest Speaker, Nephrology Rounds, Toronto General Hospital, Toronto, Ontario, December 11, 1992.

Guest Speaker, Grand Rounds, University of Chicago, Chicago, Illinois, December 16, 1992.

Guest Speaker, University of Medicine and Dentistry, New Jersey Medical School, Newark, NJ, March 1, 1993.

Guest Speaker, Department of Surgery Seminar, University of Minnesota, Minneapolis, MN, May 3, 1993.

Guest Speaker, "Management Strategies in Treating Hypertension", The American Society of Hypertension Eighth Annual Scientific Meeting, New York, NY, May 19-22, 1993.

Guest Speaker, "New Perspectives in the Management of Renal Disease", Sixth European Meeting on Hypertension, Milan, Italy, June 3, 1993.

Guest Speaker, "XIIth International Congress of Nephrology", Jerusalem, Israel, June 13-18, 1993.

Guest Speaker, "Simposio Internacional Sobre Factores de Riesgo Cardiovascular", Hospital Universitario "Germans Trias i Pujoi", Barcelona, Spain, June 21-22, 1993.

Co-chairman, Mini Symposium, "Role of endothelium in drug effects", 5<sup>th</sup> International Symposium on Cardiovascular Pharmacology, University of Minnesota, Minneapolis, MN, August 16-20, 1993.

Guest Speaker, "The Royal College of Physicians and Surgeons of Canada, Vancouver, B.C., Sep 9-13, 1993.

Guest Speaker, Third International Meeting on the Biology of Nitric Oxide, Cologne, Germany, October 3-6, 1993.

Visiting Professor, Georgetown University Medical Center and George Washington University Medical Center, Washington, D.C., October 27 and 28, 1993.

Guest Speaker, Annual Scientific Meeting, The National Kidney Foundation 43<sup>rd</sup> Annual Meeting, Boston, Massachusetts, November 13, 1993.

Program Chairman, "Mechanisms of Vascular Injury in Renal Disease and Transplantation," Satellite Symposium at the Annual Meeting of the American Society of Nephrology, Boston, Massachusetts, Nov. 15, 1993.

Guest Speaker, Basic Science Symposium, Twenty-Sixth Annual Meeting of the American Society of Nephrology in Boston, Massachusetts, Nov. 16, 1993.

Guest Speaker for Nephrology Grand Rounds, "Renal Issues in Hypertension," Medical College of Virginia Hospitals, Richmond, Virginia, Jan. 19, 1994.

Guest Speaker for Renal Grand Rounds, "Renal Issues in Hypertension," Baylor College of Medicine and the Methodist Hospital, Jan. 26, 1994.

Guest Speaker, International IgA Nephropathy Symposium, Adelaide - Australia, February 28-March 1, 1994.

Guest Speaker, "Physiology and Pathophysiology of the Vascular Wall," Sherbrooke, Quebec, Canada, April 1, 1994.

Guest Speaker, "Alberta Nephrology Days," University of Alberta and University of Calgary, Jasper, Alberta, April 8-11, 1994.

Visiting Professor, Bowman Gray, University of North Carolina, Chapel Hill, North Carolina, Duke University, Raleigh, North Carolina, April 13-14, 1994.

Guest Speaker, American Society of Hypertension, New York, New York, May 10-14, 1994.

Guest Speaker, "institut de Recherches Internationales Servier," Courbevoie, France, May 24, 1994.

Visiting Professor, "Ospedale Maggiore di Milano, Divisione di Nefrologia e Dialisi," Milan, Italy, May 31, 1994.

Guest Speaker, 2<sup>nd</sup> International Symposium on Lipids, Atherosclerosis and the Kidney, Porto Cervo, Italy, June 3-5, 1994.

Visiting Professor, The Long Island College Hospital, Brooklyn, NY June 29-30, 1994.

Visiting Professor, The University of South Alabama College of Medicine, Mobile, Alabama, August 11, 1994.

Visiting Professor, Henry Ford Hospital, Detroit, Michigan, August 15, 1994.

**Visiting Professor, University of California, San Francisco, CA, August 16, 1994**

Visiting Professor, Stanford University Medical School, August 18, 1994.

Visiting Professor, Santa Clara Valley Medical Center, San Jose, CA, August 19, 1994.

Visiting Professor, University of Maryland School of Medicine, Maryland, Sep 20-21, 1994.

Guest Speaker, "IX Congreso Latinoamericano de Nefrologia", San Juan, Puerto Rico, October 23, 1994.

Satellite Symposium Chairman, American Society of Nephrology Meeting, Orlando, Florida, October 27, 1994.

Guest Speaker, Visiting Professor, Boston University School of Medicine, Boston, MA, Jan 25, 1995.

Visiting Professor, Medical University of South Carolina, Charleston, SC, Feb 7, 1995.

Guest Speaker, Hypertension and the Kidney - New Anti-Hypertensive Agents in Renal Patients Meeting, Germany, Apr 29, 1995

Guest Speaker, Sociedad de Hipertensión Arterial de México, A.C., Mexico, May 5-6, 1995.

Guest Speaker, Canadian Nephrology Bureau, New York, NY, May 16, 1995.

Guest Speaker, American Geriatrics Society, Washington, DC, May 18, 1995

Guest Speaker, XIth Scientific Meeting, Inter-American Society of Hypertension, Montreal,

Canada, June 17-20, 1995.

Session Chairman, XIIIth International Congress of Nephrology, Madrid, Spain, July 2-6, 1995.

Guest Speaker, Symposium - Renal Pathology Society - The Kidney in Hypertension, 45<sup>th</sup> Annual Meeting of the National Kidney Foundation, San Diego, CA, Nov 5, 1995.

Program Chairman, 6<sup>th</sup> Annual Nephrology Issues for the Nineties, Satellite Symposium at the Annual Meeting of the American Society of Nephrology, San Diego, CA, Nov 5-8, 1995.

Guest Speaker, Spanish Foundation for Cardiovascular Research Meeting, Madrid, Spain, November 24-25, 1995.

Guest Speaker, University of Miami, Pediatric Nephrology Seminar XXIII, Miami, FL, February 3-7, 1996

Guest Speaker, Nile Fibrosis Workshop, Egypt, February 26-March 1, 1996.

Guest Speaker, Spanish Society of Hypertension, Madrid, Spain March 7-9, 1996.

Guest Speaker, "Acute Renal Failure in the 21<sup>st</sup> Century", National Institutes of Health, Washington DC, May 6-8, 1996

Visiting Professor, Hahnemann University and Medical College of Pennsylvania, Philadelphia, PA, May 15, 1996.

Guest Speaker, American Society of Hypertension Symposium ("The Role of Insulin in Vascular Disease and Hypertension"), New York, NY, May 15-19, 1996.

Guest Speaker, 16<sup>th</sup> Scientific Meeting of the International Society of Hypertension", Glasgow, United Kingdom, June 23-27, 1996.

Guest Speaker, Diabetic Nephropathy Workshop, Vienna, Austria, Sep 6-7, 1996.

Guest Speaker, Second International Conference on Lipoprotein, Oxidation and Atherosclerosis, Pavia, Italy, September 12-14, 1996.

Guest Speaker, 50<sup>th</sup> Annual Fall Conference & Scientific Sessions of the Council for High Blood Pressure Research, Chicago, IL, September 17-20, 1996.

Visiting Professor and Guest Speaker, Washington Hospital Center, Washington, DC, October 16, 1996.

Guest Speaker, Update in Hypertension, Mexico City, October 29-30, 1996.

Chairman, 7<sup>th</sup> Annual Satellite Symposium, Nephrology Issues for the Nineties, American Society of Nephrology Meeting, New Orleans, LA, November 4, 1996.

Guest Speaker, Meeting of Vascular Medicine, Mar del Plata, Argentina, November 25-29, 1996.

Guest Speaker, Medical Grand Rounds, University of Miami School of Medicine, Miami, Florida, January 22, 1997.

Guest Speaker, Institut de Recherches Internationales SERVIER, Paris, France, February 6, 1997.

Guest Speaker, International Meeting on Cardiovascular Risk Factors, Malaga, Spain, February 8, 1997.

Guest Speaker, Inter-American Society of Hypertension XIIIth Scientific Meeting, Mexico City, March 15-18, 1997.

Guest Speaker, International Meeting of Hypertension, Seville, Spain, April 11-12, 1997.

Guest Speaker, University of Manitoba, Health Science Center, Winnipeg, Manitoba, May 22, 1997.

Guest Speaker, American Society of Hypertension Twelfth Scientific Meeting, San Francisco, California, May 28, 1997.

Guest Speaker, Endothelial Function and Cardiovascular Disease in Humans, Camogli, Italy, June 8-9, 1997.

Guest Speaker, Il Jornadas del Consejo de Hipertensión Arterial, de la Asociación Nefrológica de la Ciudad de Buenos Aires, Argentina, August 8-9, 1997.

**Guest Speaker, Loyola Medical School, Chicago, Illinois, September 4, 1997**

Guest Speaker, 51<sup>st</sup> Annual Fall Conference & Scientific Sessions of the Council for High Blood Pressure Research, "Hypertensive Renal Injury and Its Relationship With Other End-organ Injury", Washington, DC, September 16-19, 1997.

Invited speaker, 1<sup>st</sup> International Symposium on Angiotensin II Antagonism, London, United Kingdom, September 28-October 1, 1997

Guest speaker, II Congress International, Renal Hypertension, Florence, Italy, October 24-28, 1997.

Symposium Chairman, Satellite Symposium, Unresolved Issues in Chronic Renal Failure: Progression of Cardiovascular Risk Factors, what should we do?@ American Society of Nephrology Meeting, San Antonio, Texas, November 3, 1997.

Guest speaker, International Symposium, Hypertension and the Kidney, Madrid, Spain, January 28- February 1, 1998.

Guest speaker, Congress of Cardiology, Philippines, February 1998

Guest speaker, 8<sup>th</sup> Annual Alberta Nephrology Days, Edmonton, Alberta, March 21,22, 1998.

Visiting Professor, Grand Rounds, University of Kentucky, Lexington, Kentucky, April 8, 1998.

Guest speaker, Turkish Congress of Cardiology, Istanbul, May 1998.

Guest speaker, Essential Hypertension as a Renal Disease, Warsaw, Poland, June 3, 1998.

Guest speaker, 17<sup>th</sup> Scientific Meeting of the International Society of Hypertension, Amsterdam, June 7-11, 1998.

Guest Speaker, Mexican Society of Hypertension, Guatemala City, Guatemala, Sep 2-3, 1998.

Session moderator, 52<sup>nd</sup> Annual Fall Conference and Scientific Sessions, American Heart Association, Philadelphia, PA., Sept. 14-18, 1998.

Guest Speaker, Spanish Society of Nephrology and Hypertension, Madrid, Spain, October 5-9, 1998.

Guest Speaker, Spanish Society of Nephrology, Sevilla, Spain, October 2-10, 1998.

Guest Speaker, Spanish Society of Nephrology and Hypertension, Madrid, Spain, October 5-9, 1998.

Session Chairman, American Society of Nephrology, Philadelphia, PA, October 26, 1998.

Guest Speaker, Argentina Congress of Cardiology, Buenos Aires, Argentina, November 18-20, 1998.

Guest speaker, EuroTransMed satellite broadcast, Progression of Renal Diseases, London, UK December 1, 1998.

Visiting Professor, Endocrine Research Conference, Indiana University, Indianapolis, IN, December 14, 1998.

Invited Speaker, International Forum on Angiotensin II Receptor Antagonism, Monte Carlo, January 27-30, 1999.

Invited Speaker, Symposium Internacional Diabetes y Riñón (Diabetic Nephropathy), Barcelona, Spain, February 4-6, 1999.

Invited Speaker, Conference Internazionale "Rene e l'ipertension, Florence, Italy, April 17, 1999.

Invited Speaker, Grand Rounds, Rush University, Chicago, IL, May 4, 1999.

Invited Speaker, Inter-American Society of Hypertension, Buenos Aires, May 7-11, 1999.

Invited Speaker, American Society of Hypertension Meeting, New York, NY, May 19-21, 1999.

Visiting Professor, Renal Conference, Miami VA Medical Center and University of Miami School of Medicine, July 30, 1999.

Invited Speaker, XVII Inter-American Congress of Cardiology, Buenos Aires, Argentina, August 22-25, 1999.

Session Chairman, 53<sup>rd</sup> Annual Fall Conference and Scientific Sessions, American Heart Association, Miami, FL, September 13-15, 1999.

Visiting Professor, Hospital Universitario, Madrid Spain, October 22-24, 1999.

Invited Speaker, American Society of Nephrology, New Aspects of Nitric Oxide Biology and Regulation Symposium, Miami Beach, Florida, November 6, 1999.

Visiting Professor, Keck School of Medicine, University of Southern California, Los Angeles, December 2, 1999.

Visiting Professor, Grand Rounds, Louisiana State University, New Orleans, March 14, 2000.

**Visiting Professor, Mayo Clinic, Rochester, MN, Mar 27, 2000**

Invited speaker, and Co-Chair for Hypertension and Endothelial Dysfunction session, 15<sup>th</sup> Scientific Meeting of the American Society of Hypertension, New York, May 16-20, 2000.

Invited Speaker, Cardiovascular Disease: Rethinking Hypertension Management Symposium, Henry Ford Health System, Detroit, Michigan, June 10, 2000.

Invited Speaker, Cardiovascular Disease Management in the Renal Patient: The Changing Paradigm of Prevention and Treatment Symposium, American Society of Nephrology, Toronto, Canada, October 14, 2000.

Co-moderator, A New Look at the Renin-Angiotensin-Aldosterone Axis in Progressive Renal and Cardiac Diseases, Symposium, American Society of Nephrology, Toronto, Canada, October 15, 2000.

Invited speaker, 9<sup>th</sup> National Congress of Cardiology of Mexico, Puerto Vallarta, Mexico, October 27 November 1, 2000.

Session Chair/Abstract Session Moderator, and Invited Speaker, Cardiovascular Seminar, 73<sup>rd</sup> Scientific Sessions, American Heart Association, November 12-15, 2000, New Orleans, Louisiana.

Invited speaker, American Heart Association 55<sup>th</sup> Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure Research, Workshop on Genetics and its Approaches to the Understanding of Mechanisms Involved in Hypertension and Cardiovascular Disease, Chicago, IL, September 22-25, 2001.

Invited speaker, American Society of Nephrology and ISN: World Congress of Nephrology 2001 Meeting, Advances in General and ICU Nephrology and Transplantation: An Update in Spanish, San Francisco, CA, October 11-17, 2001

Invited speaker, American Heart Association, Council for High Blood Pressure Research Scientific Sessions 2001” and recipient of the 2001 Lewis K. Dahl Memorial Lecture Award, Anaheim, CA, November 11-14, 2001.

Invited speaker, Advances in Nephrology 2002, Nitric oxide in cardiovascular disease and Angiotensin II axis, Barcelona, Spain, January 23-25, 2002.

Invited speaker, Third Annual John H. Laragh Conference on Advances in Hypertension Research, Palm Beach, Florida, January 31-February 2, 2002

Invited speaker at the Annual Rome Conference Renin-Angiotensin-aldosterone axis in Progressive renal and cardiovascular diseases, Rome, Italy, February 21-23, 2002.

Invited speaker at the Annual Meeting of the New York Society of Nephrology, New York, April 10-11, 2002.

Invited speaker at the Second Annual Nephrology Update in Spanish of the Clinical Nephrology Meeting 2002, National Kidney Foundation, Chicago, IL, April 17-21, 2002.

Invited speaker at the XV Annual General Meeting of the EDNSG, Barcelona, Spain, May 3-4, 2002.

Guest Speaker, 17<sup>th</sup> Annual Scientific Meeting of the American Society of Hypertension, New York, New York, May 14-18, 2002.

Guest Speaker, Annual Meeting of Mexican Society of Nephrology, Mérida, Mexico, Sept 18-20, 2002.

Invited speaker at the AHA Scientific Sessions 2002, Orlando, FL, November 24-27, 2002.

Invited speaker at the Annual American Society of Nephrology 2002, Philadelphia, PA, October 30-November 4, 2002.

Invited speaker, American Heart Association 56<sup>th</sup> Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure Research, in Chicago, IL, September November 16-19, 2002.

Guest speaker, Mechanisms for Diseases (MOD) University of Miami School of Medicine, September, 2003

Guest speaker, Endocrinology Grand Rounds, University of Miami School of Medicine, October 9, 2003.

Invited speaker, 10<sup>th</sup> Annual COSEHC National Scientific Sessions, Coral Gables, FL, October 16, 18, 2003.

Invited speaker, National Kidney Foundation 2004 Clinical Meetings, April 2004.

Chairman, New Insights in the Pathophysiology and Treatment of Essential Hypertension, Pisa, Italy, May 2004.

Invited speaker, NitroMed Scientific Advisory Board Meeting, Boston, MA, June 2004.

Invited speaker, American Society of Hypertension 19<sup>th</sup> Annual Scientific Meeting and Exposition, New York, NY, May 2004.

Invited speaker, 11<sup>th</sup> International/5<sup>th</sup> National Congress of Medicine, Santiago de Compostela, Spain, June 2004.

Visiting Professor, Medical College of Georgia, Augusta, GA. November 18, 2004.

Visiting Professor, University of Alabama, Birmingham, AL. November 11-12, 2004.

Invited Guest Speaker, American Diabetes Association, Post graduate course, New York, NY, February 5, 2005.

Guest Speaker, American Society of Hypertension, Hypertension in Hispanics: A Public Health Problem. May 2005

Visiting Professor, University of Bologna, Italy Apr. 2005

Invited Speaker, Novartis Pharmaceuticals Corporation, "Hypertension, Endothelium and Cardiovascular Risk: Therapeutic Implications" June 2005

Invited Speaker, Consejo Argentino de Hipertension Oct. 2005

Visiting Professor, Duke Medical School Dec. 2005

Invited guest speaker, New Insights in the Pathophysiology and treatment of hypertension, Pisa, Italy May 2006.

Guest Speaker, 21<sup>st</sup> Annual American Society of Hypertension Scientific Meeting, "Insulin Resistance an Endothelial Dysfunction Therapeutics Intervention." May 2006

Guest Speaker, 8<sup>th</sup> annual Meeting for new Research in cardiovascular Kidney Disease, Georgetown University, Amelia Island Plantation, Jacksonville, FL May 2006

Invited Guest Speaker, The Society of Nephrology and Hypertension of Puerto Rico Annual Convention Rio Grande, Puerto Rico July 27—30 2006

Guest Speaker, 5<sup>th</sup> Conference of Iber America “Glut 1 and hypertension, interaction between hypertension and metabolic factors” Madrid, Spain October 2006

Invited Guest Speaker, American Society of Nephrology Renal Week 2006 “The Three Horses of Apocalypse: Inflammation, Injury, and Angiotensin” San Diego, CA November 2006

Invited Guest Speaker, 1<sup>st</sup> International Regional meeting of hypertension In Mexico “Insulin Resistance and endothelial dysfunction: Therapeutic Interventions” October 4-6 2006

Invited Guest Speaker, University of Virginia, Renal Grand Rounds “Interaction of NO and Ang II; not all Hypertensions are the same” October 2006

Guest Speaker, Socedad Mejjicana De Hipertension October 2006, Mexico

Guest Speaker, and Award Honorary member, Spanish Society of Hypertension, March 2007

Guest Speaker, Inter-American Society of Hypertension XIVth Annual National Scientific Sessions in Miami, Beach Interaction of Nitric Oxide and Angiotensin II May 2007

Guest Speaker, International Society of Hypertension in Blacks, “Endothelial Dysfunction: A General Discription, Orlando, Florida June 24, 2007

Guest Speaker, Argentine Society of Nephrology, Rosario, Argentina, October 2007

Guest Speaker, University of Miami, Winter Course “Interaction between Ang II and Nitric Oxide”, Miami, Florida January 2008

Guest Speaker, University of Miami, Pediatric Nephrology Seminar XXXV, Miami Beach, FL March 7-9, 2008

Guest Speaker, “Annual Hadad lecture, Department of Medicine, Georgetown University April 2008

Guest Speaker, American Society of Hypertension 23<sup>rd</sup> Annual Meeting, New Orleans, Louisiana, May 2008

**Teaching Awards Received**

Excellency in Resident Teaching and Education, University of Miami, May 2003-2004

Student trainee Award University of Miami, 2002-2003

Teaching Specialization

1981-1994 Renal curriculum for medical students -University of Minnesota

1981-2001 Supervision of 3<sup>rd</sup> and 4<sup>th</sup> year Medical Students during clinical renal rotation

Teaching Awards- University of Minnesota

Medical Residents 1996, 97 and 98.

Teaching and Dissertation

1982-2001 Renal and Hypertension Curriculum for Internal Medicine Residents

**VII. University Committee:**

Post-doctoral Fellowship Committee, University of Minnesota - until 2001

Member of the Scientific Advisory Committee, University of Miami 2006-present

Member of the Ethics Group, University of Miami 2006-present

**31. Post-doctoral Supervision  
Past and Current Students**

<b>Trainee</b>	<b>Training Level (pre/post)</b>	<b>Training Period</b>	<b>Institution, prior to entering into training</b>	<b>Research Interest</b>	<b>Current positions (past students)</b>
Charles Sweeney	Post	1989-1991	Fellow, Univ of Minnesota	Oxidant induced endothelial injury	Private Practice
Judit Nagy	Post	1990-1991	MD, PhD Univ Med School of Pecs, Hungary	Endothelial function in dislipidemia	MD, PhD U Med School of Pecs, Hungary
Gunnar Westberg	Post	1993-1994	Assoc Prof Med Goteberg, Sweden	Biology of nitric oxide	Assoc Prof. Medicine
Domingo del Castillo	Post	1993-1994	Univ of Cordoba	Nitric oxide in sepsis	Chief of Transplant, Univ of Cordoba
Edgar A. Jaimes	Post	1993-1994 & 1995-1998	University of Colombia, Bogota, Colombia	Biology of nitric oxide	University of Minnesota
Hiroshi Hayakawa	Post	1994-1996	Faculty of Medicine, Univ of Tokyo, Tokyo, Japan	Endothelium In hypertension	Chief Nephrology Kanto Central Hospital, Tokyo
Josep Galceran	Post	1995-1996	Univ of Barcelona, Barcelona, Spain	Angiotensin II and oxidant injury	Chief of Nephrology, Hospital de Palamos, Spain
Ahmed Adam	Post	3/1999-3/ 2001	Univ. of Alexandria Alexandria, Egypt	Hypertension & endothelial function	Chief of Nephrology, Alexandria Hospital
Ming Sheng Zhou	Post	April 2000 - present	Kagawa Univ, Japan	Hypertension & salt sensitivity	Currently Research Assistant Professor, University of Miami
Maddalena Veronesi	Post	May 2000-present	Univ of Bologna, Bologna, Italy	Estrogens and vascular function	Assistant Professor of Nephrology

Ivonne Schulman	Post/ Jr. Faculty	July 2002	Univ of Miami
Hypertension aging endothelium			

**Research Support.** List selected ongoing or completed (during the last three years) research projects (federal and non-federal support). Begin with the projects that are most relevant to the research proposed in this application. Briefly indicate the overall goals of the projects and your role (e.g. PI, Co-Investigator, Consultant) in the research project. Do not list award amounts or percent effort in projects.

Title: Hispanic Community Health Study  
 NIH/NHLBI 20% Effort  
 Role: Co- PI ADC 670,501  
 Dates: 2006-2013 Total Budget 9,872,856.

Summary: This longitudinal, epidemiological, multi-center study will identify health status, chronic disease risk factors and protective health behaviors in 16,000 Hispanic/Latino participants, of whom 4,000 primarily Cuban participants will be examined in Miami-Dade County, FL.

Title: Biobehavioral Bases of CHD Risk and Management  
 NIH/NHLBI 25% Effort  
 Role: Investigator ADC 1,503,989  
 Dates: 2006-2011 Total Budget 11,974,484

Summary: This project will assess the role of behavior in the progression of atherosclerosis in the Watanabe Heritable Hyperlipidemic Rabbit by examining the influence of social environment on hyperlipidemic, oxidative, and inflammatory disease processes.

Title: Mechanisms of Renal and Vascular Injury  
 VA merit awards  
 Role: PI

**Dates: 1982-2006 ; 2007-2009 SFVAFRE**

Summary: The main objective of these grants was/is is to study mechanisms of vascular and kidney injury and in more recent years to study the role of the interaction among Angiotensin II, Nitric Oxide and Oxidative stress in hypertensive end-organ injury

Title: COX-2 and the Renal Angiotensin System in Hypertensive Renal Disease  
 VA merit awards 10% Effort  
 Role: Collaborator Total Budget 342,300  
 Dates: 10/1/2004 – 9/30/2007

Summary: The main objective of this project is to determine the interaction between COX-2 and the renin angiotensin system in the pathogenesis of end-organ injury in hypertension.

Flight Attendants Medical Research Institute  
 Young Investigator Award  
 Title: Mechanisms of Endothelial Dysfunction in Smokers  
 Role: Mentor. 10% Effort  
 Dates: 7/01/03-6/30/06 ADC 40,000

